Form 4: Acadia Pharmaceuticals Officer James Kihara Reports Stock Transactions

James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, reports acquisition and disposal of common stock and restricted stock units to cover withholding taxes.

Summary

• On April 5, 2024, James Kihara acquired 2,010 shares of common stock through the vesting of restricted stock units and disposed of 2,010 shares to cover withholding taxes.
• On April 7, 2024, Kihara acquired 1,489 shares of common stock through the vesting of restricted stock units and disposed of 1,489 shares to cover withholding taxes.
• On April 8, 2024, Kihara sold 1,028 shares at a weighted average price of $17.87, with prices ranging from $17.763 to $17.87.
• Also on April 8, 2024, Kihara sold 762 shares at a weighted average price of $17.87, with prices ranging from $17.7267 to $17.87.
• Following these transactions, Kihara directly owns 13,100 shares of Acadia Pharmaceuticals common stock and 4,020 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reports routine transactions related to stock vesting and tax obligations. There is no indication of positive or negative sentiment towards the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company officer.
• Employees holding restricted stock units are affected by the vesting schedule and associated tax obligations.

Key Dates